Clinical trials of PD-1/PD-L1 antibody immunotherapy for glioma are relatively delayed, largely remaining on phase II (e.g., NCT01952769, Pidilizumab) and phase III (e.g., NCT02017717, Nivolumab) (Filley et al., 2017; Maxwell et al., 2017). The gene discussed is PDCD1; the disease is glioma.